2017 has been an exciting year during which the iM4TB Foundation made many accomplishments. Pre-clinical trials were successfully completed with PBTZ169 continuing to show all its earlier promise at being a new cure for tuberculosis. Phase Ia of clinical trials was approved by Swissmedic and are moving ahead at the CHUV; this was largely made possible by a very generous donation from the Bill and Melinda Gates Foundation.
There is still a lot to do before this new possibility moves from trials to those suffering from tuberculosis but we are confident that, as long as funding stays available, PBTZ169 will be a breakthrough in the fight for a TB cure.
